Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.64 |
| ▸ | SIGMAR1 | Q99720 | 9/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.56 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7624612 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL854090 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL1773132 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7612611 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL7563162 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL11806608 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL2162933 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL79441 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL17027772 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT | |
| SCHEMBL3310359 | 1.00 | TDP1 (0.64) | TDP1SIGMAR1MAOAMAOBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140296485-A1 | ANIONIC DISPLACER MOLECULES FOR HYDROPHOBIC DISPLACEMENT CHROMATOGRAPHY | PNC BANK, NATIONAL ASSOCIATION | 2014-10-02 | — | — | US | disclosed |
| US-20110295029-A1 | NANOPARTICLE DISPERSIONS WITH LOW AGGREGATION LEVELS | LUCENT TECHNOLOGIES, INC. (US) | 2011-12-01 | — | — | US | disclosed |
| US-8012564-B2 | Nanoparticle dispersions with low aggregation levels | ALCATEL LUCENT (FR) | 2011-09-06 | — | — | US | disclosed |
| US-20080017848-A1 | NANOPARTICLE DISPERSIONS WITH LOW AGGREGATION LEVELS | LUCENT TECHNOLOGIES (US) | 2008-01-24 | — | — | US | disclosed |
| CN-1105558-C | 2,2-dichloroalkane carboxylic acids, process for preparing the same, medicament containing the same and use for treating insulin resistance | ROCHE DIAGNOSTICS GMBH (DE) | 2003-04-16 | — | — | CN | disclosed |
| EP-0790824-B1 | 2,2-DICHLOROALKANE CARBOXYLIC ACIDS, PROCESS FOR PREPARING THE SAME, MEDICAMENT CONTAINING THE SAME, AND USE THEREOF FOR TREATING INSULIN RESISTANCE | ROCHE DIAGNOSTICS GMBH (DE) | 2002-02-06 | — | — | EP | disclosed |
| US-5968982-A | TREATMENT OF DIABETES | ROCHE DIAGNOSTICS GMBH (DE) | 1999-10-19 | — | — | US | disclosed |
| CN-1171050-A | 2, 2-Dichloroalkanecarboxylic acids, method for the production thereof, medicaments containing the same and use thereof for the treatment of insulin resistance | BOEHRINGER MANNHEIM GMBH (DE) | 1998-01-21 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110295029-A1 | NANOPARTICLE DISPERSIONS WITH LOW AGGREGATION LEVELS | CCNO, FLOT1, TSPO | TDP1 1202/4885SIGMAR1 1102/4885MAOA 2748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.